A THC Kinase Study Distinguished Reversing Tolerance From Reducing the Initial Drug Effect

A 2003 study found that selected kinase inhibitors reversed THC antinociceptive tolerance while others did not. One higher-dose intervention reduced THC's acute antinociceptive effect, illustrating a different outcome from reversing tolerance.

The panel included useful negatives

The study tested interventions directed at several kinases. Some did not affect tolerance under the tested conditions, while PKA and Src-related inhibition produced reversal findings. These null comparisons prevent interpreting the result as a property of kinase inhibition generally.

Acute efficacy needed a separate control

At a higher dose, the PKC-directed intervention attenuated THC antinociception in non-tolerant mice. A smaller acute response is not evidence of improved tolerance or restored drug sensitivity. Conflating these comparisons would reverse the practical meaning of the observation.

A biochemical correlate added another layer

PKA inhibition also reversed a tolerance-associated decrease in dynorphin release in rats. That connection supported the authors' mechanism argument but did not establish that one biochemical signal fully explained all behavioral responses. Species and assay differences also remained relevant.

Interpreting the evidence

The experiment supports retaining acute-response controls, ineffective interventions and behavioral outcomes together. It does not provide a clinical way to reverse cannabis tolerance, justify medication changes or establish that a research inhibitor is safe or selective in people.

Related reading: interpreting cannabis tolerance claims.

Research reference

Lee MC; Smith FL; Stevens DL; Welch SP (2003). The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol. The Journal of pharmacology and experimental therapeutics. doi:10.1124/jpet.102.044446.

This analysis draws on the supplied study abstract.